TrialArthritis research & therapy2020

The Janus kinase 1/2 inhibitor baricitinib reduces biomarkers of joint destruction in moderate to severe rheumatoid arthritis.

Christian S Thudium et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.